Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS
T Osterholt, P Todorova, L Kühne, R Ehren… - Scientific Reports, 2023 - nature.com
Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are
glomerulopathies associated with nephrotic syndrome. Primary forms of these diseases are …
glomerulopathies associated with nephrotic syndrome. Primary forms of these diseases are …
Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review
A Kronbichler, J Kerschbaum… - American journal of …, 2014 - karger.com
Background: Minimal change disease (MCD) and focal segmental glomerulosclerosis
(FSGS) remain a therapeutic challenge, since steroids and other immunosuppressive …
(FSGS) remain a therapeutic challenge, since steroids and other immunosuppressive …
[HTML][HTML] Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis
H Ren, L Lin, P Shen, X Li, J Xie, X Pan, W Zhang… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Rituximab (RTX) may benefit patients with glomerular disease who suffer from focal
segmental glomerular sclerosis (FSGS) or minimal change disease (MCD). Here, we have …
segmental glomerular sclerosis (FSGS) or minimal change disease (MCD). Here, we have …
Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review …
Background The efficacy and safety of rituximab (RTX) in adult frequent-relapsing (FR) or
steroid-dependent (SD) nephrotic syndrome (NS), including minimal change disease (MCD) …
steroid-dependent (SD) nephrotic syndrome (NS), including minimal change disease (MCD) …
[PDF][PDF] Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases
A Kronbichler, P König, M Busch, G Wolf… - Wien Klin …, 2013 - academia.edu
Background Minimal change disease (MCD) and focal segmental glomerulosclerosis
(FSGS) are common causes of nephrotic syndrome in children and adults. However …
(FSGS) are common causes of nephrotic syndrome in children and adults. However …
Consolidation treatment and long-term prognosis of rituximab in minimal change disease and focal segmental glomerular sclerosis
L Lin, W Wang, YF Wu, JY Xie, X Li… - Drug Design …, 2021 - Taylor & Francis
Purpose There is currently a lack of studies investigating long-term prognosis and the
necessity of further rituximab (RTX) consolidation treatment for minimal change disease …
necessity of further rituximab (RTX) consolidation treatment for minimal change disease …
Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis
Background Use of rituximab (RTX) for focal segmental glomerulosclerosis (FSGS) and
minimal change disease (MCD) is widely described in children. Clinical evidence in adults is …
minimal change disease (MCD) is widely described in children. Clinical evidence in adults is …
[HTML][HTML] Rituximab in adult minimal change disease and focal segmental glomerulosclerosis-What is known and what is still unknown?
Primary forms of minimal change disease and focal segmental glomerulosclerosis are rare
podocytopathies and clinically characterized by nephrotic syndrome. Glucocorticoids are the …
podocytopathies and clinically characterized by nephrotic syndrome. Glucocorticoids are the …
Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature
T Kisner, V Burst, S Teschner, T Benzing… - Nephron Clinical …, 2012 - karger.com
Abstract Background/Aims: Minimal change disease (MCD) and focal segmental
glomerulosclerosis (FSGS) are common causes of nephrotic syndrome (NS) in adults …
glomerulosclerosis (FSGS) are common causes of nephrotic syndrome (NS) in adults …
[HTML][HTML] Rituximab as initial therapy in adult patients with minimal change disease
N Guan, M Zhang, R Chen, Q Xie, CM Hao - Kidney International Reports, 2023 - Elsevier
Minimal change disease (MCD) accounts for 10% to 15% of primary nephrotic syndrome in
adults. 1 Although spontaneous remission can occur in MCD, untreated nephrotic syndrome …
adults. 1 Although spontaneous remission can occur in MCD, untreated nephrotic syndrome …